Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
EMERYVILLE, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced...
-
-- Clinical programs continue progressing, with multiple Phase 2 data catalysts from neoantigen oncology vaccine programs and additional human data evaluating self-amplifying mRNA (samRNA) vaccines...
-
-- Clinical programs continue progressing, with multiple Phase 2 data catalysts from neoantigen oncology vaccine programs and additional human data evaluating self-amplifying mRNA (samRNA) vaccines...
-
EMERYVILLE, Calif., May 02, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease...
-
EMERYVILLE, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease...
-
-- Translational immunology data and cassette design capabilities enabled development of an optimized, KRAS-specific version of “off-the-shelf” vaccine candidate now in Phase 2 (SLATE-KRAS) -- --...
-
EMERYVILLE, Calif., March 30, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease...
-
-- Four trials now initiated for CORAL, Gritstone’s second-generation COVID-19 program focused on delivering T cell enhanced self-amplifying mRNA (samRNA) vaccines -- -- Oncology programs advancing...
-
-- Oral presentation to discuss how translational immunology data enabled iterative development of an optimized, KRAS-specific version of “off-the shelf” vaccine candidate; the optimized...
-
EMERYVILLE, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease...